...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of obstetrics and gynaecology research >Prediction effects of serum CA125 decrease ratio during different cycles in relapsed ovarian cancer
【24h】

Prediction effects of serum CA125 decrease ratio during different cycles in relapsed ovarian cancer

机译：血清CA125在卵巢癌中不同循环期间降低比率的预测效应

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Aim To investigate the prognostic value of serum cancer antigen 125 (CA125) levels during chemotherapy in relapsed epithelial ovarian cancer (EOC) and to identify cut‐off values that distinguish patients who relapse beyond 12?months from those who relapse within 12?months. Methods About 93 relapsed EOC patients who received cytoreductive surgery and adjuvant chemotherapy at Obstetrics and Gynecology Hospital of Fudan University between January 2003 and March 2015 were selected. Univariate regression analysis was used to determine the significant prognostic factors. The Kaplan–Meier method was used to calculate the overall survival (OS) rate. Results The CA125 decrease ratio of more than 97.6% after the fourth chemotherapy cycle was significantly associated with relapse time ( P =?0.044). The sensitivity was 70.0%, and the specificity was 76.9%. Moreover, in all relapsed patients, the group with the CA125 decrease ratio after the fourth chemotherapy cycle of more than 97.6% had a significantly better OS than any other group ( P =?0.0019). Conclusion The CA125 decrease ratio of less than 97.6% after the fourth chemotherapy cycle can be a predictive factor for relapse within 12?months. Patients without a significant decrease in CA125 after four cycles of chemotherapy should have a more frequent follow‐up and more active re‐examination.
机译：摘要旨在探讨血清癌抗原125（CA125）水平在复发上皮性卵巢癌（EOC）期间的预后价值，并确定区分患者在12年内复发的人中复发超过12的截止值。方法选择了2003年1月至2015年1月至2015年3月在复旦大学妇产科医院接受细胞导致手术和辅助化疗的93例EOC患者。单变量回归分析用于确定显着的预后因素。 KAPLAN-MEIER方法用于计算整体存活率（OS）率。结果CA125在第四化疗循环与复发时间明显相关后，CA125降低比率超过97.6％（P = 0.044）。敏感性为70.0％，特异性为76.9％。此外，在所有复发的患者中，患有CA125的组在97.6％的第四化疗循环后的比率比任何其他组具有明显更好的操作系统（P = 0.0019）。结论第四次化疗周期后Ca125降低比率小于97.6％，在12月12日之间复发的预测因素。在四个化疗后，无需显着降低的患者应具有更频繁的随访和更积极的重新检查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号